Literature DB >> 9514046

Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas.

R Lacave1, F Coulet, S Ricci, E Touboul, A Flahault, J G Rateau, D Cesari, J P Lefranc, J F Bernaudin.   

Abstract

Identification and quantitative evaluation of drug resistance markers are essential to assess the impact of multidrug resistance (MDR) in clinical oncology. The MDR1 gene confers pleiotropic drug resistance in tumour cells, but other molecular mechanisms are also involved in drug resistance. In particular, the clinical pattern of expression of the other MDR-related genes is unclear and their interrelationships are still unknown. Here, we report standardization of the procedures used to determine a reliable method of semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) using a standard series of drug-sensitive and increasingly resistant cell lines to evaluate the expression of three MDR-related genes, i.e. MDR1 (multidrug resistance gene 1), MRP (multidrug resistance related protein) and GSTp (glutathione-S-transferase p), reported to be endogenous standard genes for normalization of mRNAs. A total of 74 breast cancer surgical biopsies, obtained before any treatment, were evaluated by this method. When compared with classical clinical and laboratory findings, GSTp mRNA level was higher in diploid tumours. However, the main finding of our study suggests a clear relationship between two of these MDR-related gene expressions, namely GSTp and MRP. This finding provides new insight into human breast tumours, which may possibly be linked to the glutathione conjugate carrier function of MRP. Well defined semiquantitative RT-PCR procedures can therefore constitute a powerful tool to investigate MDR phenotype at mRNA levels of different related genes in small and precious tumour biopsy specimens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514046      PMCID: PMC2149951          DOI: 10.1038/bjc.1998.115

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  60 in total

1.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.

Authors:  G J Zaman; M J Flens; M R van Leusden; M de Haas; H S Mülder; J Lankelma; H M Pinedo; R J Scheper; F Baas; H J Broxterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

2.  ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein.

Authors:  G Jedlitschky; I Leier; U Buchholz; M Center; D Keppler
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

Review 3.  Glutathione-associated enzymes in anticancer drug resistance.

Authors:  K D Tew
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

4.  Expression of mdr1 gene in human breast primary tumors and metastases.

Authors:  E Hennequin; C Delvincourt; C Pourny; J C Jardillier
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators.

Authors:  C Charpin; P Vielh; F Duffaud; B Devictor; L Andrac; M N Lavaut; C Allasia; N Horschowski; L Piana
Journal:  J Natl Cancer Inst       Date:  1994-10-19       Impact factor: 13.506

6.  Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.

Authors:  M J Flens; M A Izquierdo; G L Scheffer; J M Fritz; C J Meijer; R J Scheper; G J Zaman
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

7.  Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.

Authors:  K Nooter; A M Westerman; M J Flens; G J Zaman; R J Scheper; K E van Wingerden; H Burger; R Oostrum; T Boersma; P Sonneveld
Journal:  Clin Cancer Res       Date:  1995-11       Impact factor: 12.531

8.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.

Authors:  S P Cole; K E Sparks; K Fraser; D W Loe; C E Grant; G M Wilson; R G Deeley
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.

Authors:  M R Abbaszadegan; B W Futscher; W T Klimecki; A List; W S Dalton
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

10.  Cell biological mechanisms of multidrug resistance in tumors.

Authors:  S M Simon; M Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more
  4 in total

Review 1.  MRP subfamily transporters and resistance to anticancer agents.

Authors:  G D Kruh; H Zeng; P A Rea; G Liu; Z S Chen; K Lee; M G Belinsky
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

2.  The effect of different interventional treatment on P-Glycoprotein in different histopathological types and grades of primary hepatocellular carcinoma.

Authors:  E Xiao; G Hu; P Liu; D Hu; S Liu; C Hao
Journal:  J Tongji Med Univ       Date:  2000

3.  Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients.

Authors:  L Moureau-Zabotto; S Ricci; J P Lefranc; F Coulet; C Genestie; M Antoine; S Uzan; J P Lotz; E Touboul; R Lacave
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

4.  Expression of multidrug resistance-related transporters in human breast carcinoma.

Authors:  A Kanzaki; M Toi; K Nakayama; H Bando; M Mutoh; T Uchida; M Fukumoto; Y Takebayashi
Journal:  Jpn J Cancer Res       Date:  2001-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.